FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Matthews Andrea		 2. Date of Event Requiring Statement (MM/DD/YYYY)
4/17/2023 

 3. Issuer Name and Ticker or Trading Symbol

Astria Therapeutics, Inc. [ATXS]
(Last)        (First)        (Middle)

C/O ASTRIA THERAPEUTICS, INC., 75 STATE STREET, SUITE 1400		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Business Officer /
(Street)

BOSTON, MA 02109      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)  (1)8/26/2024 Common Stock 389 $432.00 D  
Stock Option (Right to Buy)  (1)3/25/2025 Common Stock 51 $663.00 D  
Stock Option (Right to Buy)  (1)2/10/2026 Common Stock 166 $274.20 D  
Stock Option (Right to Buy)  (1)9/7/2026 Common Stock 250 $258.60 D  
Stock Option (Right to Buy)  (1)2/8/2027 Common Stock 183 $74.40 D  
Stock Option (Right to Buy)  (1)7/26/2027 Common Stock 83 $76.20 D  
Stock Option (Right to Buy)  (1)2/7/2028 Common Stock 416 $76.80 D  
Stock Option (Right to Buy)  (1)9/6/2028 Common Stock 833 $42.60 D  
Stock Option (Right to Buy)  (1)2/12/2029 Common Stock 2083 $26.34 D  
Stock Option (Right to Buy)  (2)2/11/2030 Common Stock 3333 $31.92 D  
Stock Option (Right to Buy)  (3)10/6/2030 Common Stock 4166 $39.78 D  
Stock Option (Right to Buy)  (4)3/31/2031 Common Stock 66666 $17.22 D  
Stock Option (Right to Buy)  (5)2/28/2032 Common Stock 32812 $6.51 D  
Stock Option (Right to Buy)  (6)1/31/2033 Common Stock 60000 $13.36 D  
Explanation of Responses:
(1) Fully vested.
(2) This option was granted February 12, 2020 and is subject to vesting over a four-year period, with 25% of the 3,033 shares underlying the option upon grant vesting on the first anniversary of February 12, 2020 and the remainder vesting over the ensuing three years in equal monthly installments.
(3) This option was granted October 7, 2020 and is subject to vesting over a four-year period, with 25% of the 4,166 shares underlying the option upon grant vesting on the first anniversary of October 7, 2020 and the remainder vesting over the ensuing three years in equal monthly installments.
(4) This option was granted April 1, 2021 and is subject to vesting over a four-year period, with 25% of the 66,666 shares underlying the option upon grant vesting on the first anniversary of April 1, 2021 and the remainder vesting over the ensuing three years in equal monthly installments.
(5) This option was granted March 1, 2022 and is subject to vesting over a four-year period, with 25% of the 45,000 shares underlying the option upon grant vesting on the first anniversary of February 17, 2022 and the remainder vesting over the ensuing three years in equal monthly installments.
(6) This option was granted February 1, 2023 and is subject to vesting over a four-year period, with 25% of the 60,000 shares underlying the option upon grant vesting on the first anniversary of February 1, 2023 and the remainder vesting over the ensuing three years in equal monthly installments.

Remarks:
Exhibit Index: 24 - Power of Attorney; No securities are beneficially owned.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Matthews Andrea
C/O ASTRIA THERAPEUTICS, INC.
75 STATE STREET, SUITE 1400
BOSTON, MA 02109

Chief Business Officer
Signatures
/s/ Ben Harshbarger, as attorney-in-fact for Andrea Matthews4/19/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Catabasis Pharmaceuticals (NASDAQ:CATB)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Catabasis Pharmaceuticals.
Catabasis Pharmaceuticals (NASDAQ:CATB)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Catabasis Pharmaceuticals.